Salt Lake City, UT Clinical Trials Report — June 2026

For Salt Lake City residents considering participation in medical research, June 2026 presents a critical window for several clinical trials nearing their enrollment deadlines. With 49 trials closing within the next 90 days, interested individuals should act quickly to explore these opportunities.

Among these urgent opportunities, 2 trials are still seeking healthy volunteers, offering a chance to contribute to medical science without requiring a specific health condition. Across Salt Lake City, a total of 78 trials are currently recruiting healthy participants, providing numerous avenues for those eager to support research.

Key Research Areas with Impending Deadlines

Patients managing specific health conditions also have limited time to join certain studies. Trials focused on a range of conditions are among those with enrollment windows closing soon:

• Heart failure (2 trials)
• Acute lymphoblastic leukemia (1 trial)
• Asthma (1 trial)
• ARID1A gene mutation (1 trial)
• Arthroplasty replacement, knee (1 trial)
• Arthroplasty total hip replacement (1 trial)
• ALS - Amyotrophic Lateral Sclerosis (1 trial)
• Astrocytoma (1 trial)
• Astrocytoma, IDH-mutant (1 trial)
• Atrial arrhythmia (1 trial)

New Research Opportunities Emerge in Salt Lake City

This month, Salt Lake City welcomed 12 new clinical trials, a decrease from the 20 trials that opened in May 2026. Despite this dip, the city continues to host a robust research environment with 895 clinical trials currently recruiting across 266 research facilities.

June's new trials introduce significant studies from major sponsors, focusing on a variety of health challenges. These include important Phase 2 and 3 drug trials that offer participants access to cutting-edge treatments.

• Kallyope Inc. is sponsoring a notable Phase 3 study, NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This double-blind, randomized, multicenter trial aims for 1,800 participants to evaluate the efficacy, safety, and tolerability of elismetrep compared with placebo for acute migraine treatment.
• AstraZeneca is launching NCT07662213, a Phase 3 study titled "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus." This trial seeks 1,200 participants to compare elecoglipron with oral semaglutide in adults with Type 2 Diabetes Mellitus and increased cardiovascular risk.
• From Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, comes NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)." This Phase 3, randomized, double-blind, placebo-controlled study will evaluate the long-term efficacy, safety, and tolerability of aleniglipron in 1,100 participants over 76 weeks.
• Another Phase 3 study from Kallyope Inc. is NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine." This trial aims for 1,000 participants to assess the long-term safety and tolerability of intermittent elismetrep use for acute migraine attacks.
• The University of Utah is sponsoring NCT07676500, "Brief Postoperative Pain Management Intervention: Meaning Making Amendment," a randomized controlled trial involving 576 adults undergoing total knee or hip replacement surgery.
• Aspeya, Inc. is leading NCT07646613, a Phase 2 study evaluating "The Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients." This study will enroll 108 participants.

The new trials this month are exploring a range of conditions, with migraine being the most frequent. Other conditions include:

• Migraine (2 trials)
• Age-related macular degeneration (AMD) (1 trial)
• Anxiety acute (1 trial)
• Atrial fibrillation (AF) (1 trial)
• Chronic weight management (1 trial)
• HPV vaccination (1 trial)
• Idiopathic pulmonary fibrosis (1 trial)
• Non-neovascular age-related macular degeneration (1 trial)
• Obesity (1 trial)
• Overweight (1 trial)

Drug trials account for the largest share of new studies, with 6 new drug trials, followed by 3 behavioral studies. Industry sponsors are driving 7 of the new trials, while academic institutions and other organizations sponsor 5.

Salt Lake City's Leading Research Facilities

Salt Lake City is home to several prominent research institutions that consistently lead in clinical trial activity. These facilities are key destinations for individuals looking to participate in medical research:

• University of Utah (194 trials)
• Huntsman Cancer Institute/University of Utah (82 trials)
• Huntsman Cancer Institute (65 trials)
• Primary Children's Hospital (64 trials)
• Huntsman Cancer Institute, University of Utah (32 trials)
• University of Utah Health (22 trials)
• Research Site (18 trials)
• University of Utah Sugarhouse Health Center (17 trials)
• Huntsman Cancer Institute at University of Utah (17 trials)
• University of Utah Hospital (17 trials)
• LDS Hospital (16 trials)
• The University of Utah (12 trials)

The University of Utah system, including the Huntsman Cancer Institute and Primary Children's Hospital, forms the backbone of research in the city, offering diverse opportunities from oncology to pediatric care and general health studies.

Broadening Your Search: Nearby Options

While Salt Lake City offers extensive clinical trial opportunities, individuals in Utah may also find options in nearby communities. Cities with active trials include:

• Ogden (3 trials)
• Provo (3 trials)
• Bountiful (3 trials)
• Riverton (2 trials)
• Draper (2 trials)
• St. George (2 trials)
• Syracuse (2 trials)
• Sandy City (1 trial)

Who Can Participate?

Clinical trial participation is open to a diverse range of individuals. Of the 12 new trials launched this month, 10 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial includes children. No new trials this month are exclusively for females or males.

As June progresses, Salt Lake City's research community continues to drive medical innovation, offering vital opportunities for individuals to contribute to the future of healthcare, whether by addressing urgent closing deadlines or exploring new studies.